Navigation Links
CROS NT Ltd Announces Acquisition of MDSL International Ltd.

LONDON, Jan. 7, 2014 /PRNewswire-iReach/ -- As part of the CROS NT Group global growth strategy, CROS NT Ltd today announced the acquisition of MDSL International - a specialist clinical Contract Research Organization (CRO) providing biometrics services such as Clinical Data Management and Statistical services. The financial details of the transaction remain confidential.

CROS NT Ltd, the UK branch of CROS NT, sees the acquisition as an important part of the overall group strategy. The deal adds additional resources to the existing group in the UK and will provide a new headquarters for the UK company in Maidenhead, close to London. MDSL International has built a reputation for providing strong consultancy and project work coupled with excellent customer service.

Andrew MacGarvey, CEO and President of CROS NT, said, "I am delighted to expand the UK operation through this acquisition. We are adding a highly experienced team to the business and further diversifying our customer base – both important objectives of the CROS NT Group. We will move our UK Headquarters to Maidenhead, giving us a great location in terms of on-going recruitment and access by our customers given its proximity to London. Coming shortly after our acquisition of Stat-tech Services in the USA, this deal demonstrates our commitment to place expertise close to our customers and to grow to meet the increasing demand for our services."

Edmund Otun, the founder of MDSL International, said, "I am pleased to have concluded the deal with CROS NT. Being part of a larger entity allows us to provide additional resources to our existing clients – something they have been asking for. CROS NT has a very strong management team, with great experience in the CRO business. I will remain with the company providing consultancy for emerging companies seeking advice on getting their products to market or securing licencing deals."

Jo Marshall, MDSL International Managing Director, who will become the UK Country Manager for CROS NT Ltd added, "I am excited by this opportunity and looking forward to working with the CROS NT team. In addition to giving us greater critical mass here in the UK, this deal will give our existing customers access to the CROS NT technology portfolio which includes several Electronic Data Capture (EDC) platforms, a Clinical Trial Management System (CTMS), and electronic Patient Reported Outcomes (ePRO) solutions."


In its 22nd year, CROS NT is a global Contract Research Organization (CRO) specialized in clinical data services. With over 800 studies completed in a variety of therapeutic areas and indications, CROS NT has remained focused on biometrics including statistical consultancy, programming and analysis, clinical data management, medical writing, pharmacovigilance and life science technology solutions. We collect, integrate and analyze data from various sources and uses processes and technology to ensure excellent project governance, reporting and traceability. 

About MDSL International Limited

MDSL is a private company and was founded by the Executive Chairman Dr. Edmund Otun in April 1996 to provide data management and statistical services to the pharmaceutical industry. We continue today to provide a fully project managed, flexible service from start to finish on a wide range of clinical trials for our European biotechnology and pharmaceutical customers. The principles upon which the company was founded are as valid today as they were in 1996. They are to provide superior service and quality with commitment and integrity whilst providing a work life balance for employees conducive to flexibility, motivation and versatility.

Media Contact: Mary Wieder, CROS NT, +39 045 820 26 66,

News distributed by PR Newswire iReach:

Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Announces Beta Release Of "NameTag" The First Real-Time Facial Recognition App For Google Glass
2. HGH Supplements Information Website Announces New Discounts on Sytropin and Genf20 Plus
3. BBSRC announces £10M of funding for advanced scientific equipment
4. Life Sciences Discovery Fund announces R&D grants
5. Genetics Society of America announces recipients of spring 2014 DeLill Nasser Award
6. CROS NT Ltd Announces Appointment of Andrew MacGarvey as CEO
7. Biophysical Society announces speakers for Future of Biophysics Burroughs Wellcome Fund Symposium
8. SourceMedical Announces Hiring of Clinical Expert for ASC Division
9. KaloBios Announces Preliminary Phase 1 Results in Advanced Hematologic Malignancies with KB004, an Anti-EphA3 Monoclonal Antibody
10. Wyss Institute at Harvard University announces election of 2 faculty to Natl Academy of Inventors
11. Reproductive Health Matters announces publication of its latest themed issue: New development paradigm
Post Your Comments:
(Date:11/18/2015)... Nov. 18, 2015  As new scientific discoveries deepen ... and other healthcare providers face challenges in better using ... patients. In addition, as more children continue to survive ... adulthood and old age. John M. Maris, ... Hospital of Philadelphia (CHOP) . --> ...
(Date:11/17/2015)... , Nov. 17, 2015 Pressure BioSciences, Inc. ... the development and sale of broadly enabling, pressure cycling ... sciences industry, today announced it has received gross proceeds ... million Private Placement (the "Offering"), increasing the total amount ... or more additional closings are expected in the near ...
(Date:11/11/2015)... MedNet Solutions , an innovative SaaS-based eClinical technology company that ... announce that it will be a Sponsor of the ... held November 17-19 in Hamburg , Germany.  ... iMedNet , MedNet,s easy-to-use, proven and affordable eClinical ... able to deliver time and cost savings of up to ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris ... that its business and prospects remain fundamentally strong ... Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation to ... completion following review of the final interim efficacy ... 2 Primary Endpoint in men with heavily pretreated ...
(Date:11/25/2015)... CA (PRWEB) , ... November 25, 2015 , ... ... genomics company uBiome, were featured on AngelList early in their initial angel funding ... an AngelList syndicate for individuals looking to make early stage investments in the ...
(Date:11/24/2015)... 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will ... New York on Wednesday, December 2 at 9:30 a.m. ... and CEO, will provide a corporate overview. th ... at 1:00 p.m. ET/10:00 a.m. PT . Jim Mazzola ... a corporate overview. --> th Annual Oppenheimer Healthcare ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris ... of IIROC on behalf of the Toronto Stock Exchange, ... release there are no corporate developments that would cause ... --> --> About Aeterna ... . --> Aeterna Zentaris is a ...
Breaking Biology Technology: